If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2053-4213 Vol 7.1 • November 2019 • emjreviews.com<br /> INSIDE<br /> Review of<br /> ESMO 2019<br /> Barcelona, Spain<br /> Contents<br /> + EDITORIAL BOARD 4<br /> WELCOME 7<br /> FOREWORD 9<br /> + CONGRESS REVIEW<br /> Review of the European Society for Medical Oncology (ESMO) 10<br /> Congress, held in Barcelona, Spain, 27th September–1st October, 2019<br /> + CONGRESS FEATURE<br /> Balancing the Scales: The Fight for Female Representation in Oncology 24<br /> Michael Dodsworth<br /> + INTERVIEW<br /> <a title="EMJ Oncology 7.1 2019 page 1" href="http://viewer.zmags.com/publication/a1afbafc?page=1"> ONCOLOGY ISSN 2053-4213 </a> <a title="EMJ Oncology 7.1 2019 page 2" href="http://viewer.zmags.com/publication/a1afbafc?page=2"> Contents + EDITORIAL BOARD </a> <a title="EMJ Oncology 7.1 2019 page 3" href="http://viewer.zmags.com/publication/a1afbafc?page=3"> “The peer-reviewed articles in this year’s </a> <a title="EMJ Oncology 7.1 2019 page 4" href="http://viewer.zmags.com/publication/a1afbafc?page=4"> Editorial Board Editor-in-Chief Dr Ahmad Awa</a> <a title="EMJ Oncology 7.1 2019 page 5" href="http://viewer.zmags.com/publication/a1afbafc?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Oncology 7.1 2019 page 6" href="http://viewer.zmags.com/publication/a1afbafc?page=6"> Masthead Chief Executive Officer Spencer Gore</a> <a title="EMJ Oncology 7.1 2019 page 7" href="http://viewer.zmags.com/publication/a1afbafc?page=7"> Welcome Valued readers, collaborators, and f</a> <a title="EMJ Oncology 7.1 2019 page 8" href="http://viewer.zmags.com/publication/a1afbafc?page=8"> A new day for genomic profiling A new world of NGS</a> <a title="EMJ Oncology 7.1 2019 page 9" href="http://viewer.zmags.com/publication/a1afbafc?page=9"> Foreword This edition of EMJ Oncology 7.1 offers </a> <a title="EMJ Oncology 7.1 2019 page 10" href="http://viewer.zmags.com/publication/a1afbafc?page=10"> 10 ONCOLOGY • November 2019 </a> <a title="EMJ Oncology 7.1 2019 page 11" href="http://viewer.zmags.com/publication/a1afbafc?page=11"> Congress Review Review of the European Society</a> <a title="EMJ Oncology 7.1 2019 page 12" href="http://viewer.zmags.com/publication/a1afbafc?page=12"> Numerous sessions presented at the Congress provi</a> <a title="EMJ Oncology 7.1 2019 page 13" href="http://viewer.zmags.com/publication/a1afbafc?page=13"> ESMO 2019 was undoubtedly the most relevan</a> <a title="EMJ Oncology 7.1 2019 page 14" href="http://viewer.zmags.com/publication/a1afbafc?page=14"> Liquid Biopsy Successfully Used to Identify Com</a> <a title="EMJ Oncology 7.1 2019 page 15" href="http://viewer.zmags.com/publication/a1afbafc?page=15"> Combination Immunotherapy Significantly Improves </a> <a title="EMJ Oncology 7.1 2019 page 16" href="http://viewer.zmags.com/publication/a1afbafc?page=16"> Postoperative Radiotherapy No Longer Necessary i</a> <a title="EMJ Oncology 7.1 2019 page 17" href="http://viewer.zmags.com/publication/a1afbafc?page=17"> Promising Response for First-Line Immunotherapy </a> <a title="EMJ Oncology 7.1 2019 page 18" href="http://viewer.zmags.com/publication/a1afbafc?page=18"> Increased Anticancer Drug Costs: Ar</a> <a title="EMJ Oncology 7.1 2019 page 19" href="http://viewer.zmags.com/publication/a1afbafc?page=19"> Drugs Targeted to DNA Alterations may Improve </a> <a title="EMJ Oncology 7.1 2019 page 20" href="http://viewer.zmags.com/publication/a1afbafc?page=20"> First Targeted Drug to Specific Mutations for </a> <a title="EMJ Oncology 7.1 2019 page 21" href="http://viewer.zmags.com/publication/a1afbafc?page=21"> Novel Front-Line Treatment Changes Treatment </a> <a title="EMJ Oncology 7.1 2019 page 22" href="http://viewer.zmags.com/publication/a1afbafc?page=22"> Liquid Biopsy Could Play Important Role in </a> <a title="EMJ Oncology 7.1 2019 page 23" href="http://viewer.zmags.com/publication/a1afbafc?page=23"> Exciting New Prospect for Bladder Cancer Patients</a> <a title="EMJ Oncology 7.1 2019 page 24" href="http://viewer.zmags.com/publication/a1afbafc?page=24"> Balancing the Scales: The Fight for Femal</a> <a title="EMJ Oncology 7.1 2019 page 25" href="http://viewer.zmags.com/publication/a1afbafc?page=25"> time it will take to attain truly equal economic </a> <a title="EMJ Oncology 7.1 2019 page 26" href="http://viewer.zmags.com/publication/a1afbafc?page=26"> Congress Interview Prof Dr Guillem Argilés  C</a> <a title="EMJ Oncology 7.1 2019 page 27" href="http://viewer.zmags.com/publication/a1afbafc?page=27"> important as, when you are young, something o</a> <a title="EMJ Oncology 7.1 2019 page 28" href="http://viewer.zmags.com/publication/a1afbafc?page=28"> Increased research into the identification </a> <a title="EMJ Oncology 7.1 2019 page 29" href="http://viewer.zmags.com/publication/a1afbafc?page=29"> Creative Commons Attribution-Non Commercial 4.0 </a> <a title="EMJ Oncology 7.1 2019 page 30" href="http://viewer.zmags.com/publication/a1afbafc?page=30"> Inflection Point: Novel Treatment Options ar</a> <a title="EMJ Oncology 7.1 2019 page 31" href="http://viewer.zmags.com/publication/a1afbafc?page=31"> large next-generation sequencing (NGS) panel- bas</a> <a title="EMJ Oncology 7.1 2019 page 32" href="http://viewer.zmags.com/publication/a1afbafc?page=32"> Biomarkers for Immuno-Oncology Treatment Sel</a> <a title="EMJ Oncology 7.1 2019 page 33" href="http://viewer.zmags.com/publication/a1afbafc?page=33"> Poly (ADP-Ribose) Polymerase Inhibitors move into</a> <a title="EMJ Oncology 7.1 2019 page 34" href="http://viewer.zmags.com/publication/a1afbafc?page=34"> along with median PFS and OS of 6.9 months and 21</a> <a title="EMJ Oncology 7.1 2019 page 35" href="http://viewer.zmags.com/publication/a1afbafc?page=35"> compared to using a broader NGS-gene panel comes </a> <a title="EMJ Oncology 7.1 2019 page 36" href="http://viewer.zmags.com/publication/a1afbafc?page=36"> ESMO 2019, 27 September - 1 13. </a> <a title="EMJ Oncology 7.1 2019 page 37" href="http://viewer.zmags.com/publication/a1afbafc?page=37"> Looking for a new job opportunity?</a> <a title="EMJ Oncology 7.1 2019 page 38" href="http://viewer.zmags.com/publication/a1afbafc?page=38"> Abstract Reviews In the following summaries, pre</a> <a title="EMJ Oncology 7.1 2019 page 39" href="http://viewer.zmags.com/publication/a1afbafc?page=39"> support Dept. of Immuno-Gene Therapy in Mie Univ.</a> <a title="EMJ Oncology 7.1 2019 page 40" href="http://viewer.zmags.com/publication/a1afbafc?page=40"> 2. Mie University. Investigator initiated Phas</a> <a title="EMJ Oncology 7.1 2019 page 41" href="http://viewer.zmags.com/publication/a1afbafc?page=41"> A Phase II Study of Pazopanib as Fron</a> <a title="EMJ Oncology 7.1 2019 page 42" href="http://viewer.zmags.com/publication/a1afbafc?page=42"> Eligible patients with unresectable or metastatic</a> <a title="EMJ Oncology 7.1 2019 page 43" href="http://viewer.zmags.com/publication/a1afbafc?page=43"> reached) months. No new or unexpected adverse eve</a> <a title="EMJ Oncology 7.1 2019 page 44" href="http://viewer.zmags.com/publication/a1afbafc?page=44"> 100% APC 100% A</a> <a title="EMJ Oncology 7.1 2019 page 45" href="http://viewer.zmags.com/publication/a1afbafc?page=45"> events in tumour-derived cultures. Finally, the c</a> <a title="EMJ Oncology 7.1 2019 page 46" href="http://viewer.zmags.com/publication/a1afbafc?page=46"> The 2016-2019 ImmunoTOX Assessment B</a> <a title="EMJ Oncology 7.1 2019 page 47" href="http://viewer.zmags.com/publication/a1afbafc?page=47"> B with the ImmunoTOX board 25 20 15 irAE reg</a> <a title="EMJ Oncology 7.1 2019 page 48" href="http://viewer.zmags.com/publication/a1afbafc?page=48"> Measuring the Cancer Burden in Europe: the Eur</a> <a title="EMJ Oncology 7.1 2019 page 49" href="http://viewer.zmags.com/publication/a1afbafc?page=49"> ECIS - European Cancer Information </a> <a title="EMJ Oncology 7.1 2019 page 50" href="http://viewer.zmags.com/publication/a1afbafc?page=50"> Phase I Combination Dose-Finding and Phase </a> <a title="EMJ Oncology 7.1 2019 page 51" href="http://viewer.zmags.com/publication/a1afbafc?page=51"> A) Best Overall Response Patients Who Received S</a> <a title="EMJ Oncology 7.1 2019 page 52" href="http://viewer.zmags.com/publication/a1afbafc?page=52"> CONCLUSION The combination of RPh2D LEN (14 mg/m2</a> <a title="EMJ Oncology 7.1 2019 page 53" href="http://viewer.zmags.com/publication/a1afbafc?page=53"> We want you to write for the </a> <a title="EMJ Oncology 7.1 2019 page 54" href="http://viewer.zmags.com/publication/a1afbafc?page=54"> The Anticancer Power of the Immune System </a> <a title="EMJ Oncology 7.1 2019 page 55" href="http://viewer.zmags.com/publication/a1afbafc?page=55"> with TNBC (focussing on advanced or metastatic di</a> <a title="EMJ Oncology 7.1 2019 page 56" href="http://viewer.zmags.com/publication/a1afbafc?page=56"> Table 1. Recent clinical trials on immune checkpo</a> <a title="EMJ Oncology 7.1 2019 page 57" href="http://viewer.zmags.com/publication/a1afbafc?page=57"> Table 1. continued Durvalumab anti-PD-L1 antibody</a> <a title="EMJ Oncology 7.1 2019 page 58" href="http://viewer.zmags.com/publication/a1afbafc?page=58"> At present, there is a need to explore the role o</a> <a title="EMJ Oncology 7.1 2019 page 59" href="http://viewer.zmags.com/publication/a1afbafc?page=59"> chemotherapy (CHT) and radiotherapy, and this may</a> <a title="EMJ Oncology 7.1 2019 page 60" href="http://viewer.zmags.com/publication/a1afbafc?page=60"> Switzerland).16 PD-L1 expression was assessed vi</a> <a title="EMJ Oncology 7.1 2019 page 61" href="http://viewer.zmags.com/publication/a1afbafc?page=61"> progress in molecular characteristics of TNBC, no</a> <a title="EMJ Oncology 7.1 2019 page 62" href="http://viewer.zmags.com/publication/a1afbafc?page=62"> inhibitors in cancer therapy. J Biomed Res 2018;3</a> <a title="EMJ Oncology 7.1 2019 page 63" href="http://viewer.zmags.com/publication/a1afbafc?page=63"> Epithelial Myoepithelial Carcinoma of the H</a> <a title="EMJ Oncology 7.1 2019 page 64" href="http://viewer.zmags.com/publication/a1afbafc?page=64"> BACKGROUND Epithelial myoepithelial carcinoma </a> <a title="EMJ Oncology 7.1 2019 page 65" href="http://viewer.zmags.com/publication/a1afbafc?page=65"> A B Figure 2: (A) photomi</a> <a title="EMJ Oncology 7.1 2019 page 66" href="http://viewer.zmags.com/publication/a1afbafc?page=66"> The patient underwent surgical resection of </a> <a title="EMJ Oncology 7.1 2019 page 67" href="http://viewer.zmags.com/publication/a1afbafc?page=67"> carcinoma of the parotid gland: Clinicopathologic</a> <a title="EMJ Oncology 7.1 2019 page 68" href="http://viewer.zmags.com/publication/a1afbafc?page=68"> PARP Inhibitors as a Novel Treatment Strategy </a> <a title="EMJ Oncology 7.1 2019 page 69" href="http://viewer.zmags.com/publication/a1afbafc?page=69"> and ovarian cancer (OC) has been reported in wome</a> <a title="EMJ Oncology 7.1 2019 page 70" href="http://viewer.zmags.com/publication/a1afbafc?page=70"> At different points of the cell cycle, cells can </a> <a title="EMJ Oncology 7.1 2019 page 71" href="http://viewer.zmags.com/publication/a1afbafc?page=71"> Table 1 continued. Olaparib SOLO2, Phase III NCT0</a> <a title="EMJ Oncology 7.1 2019 page 72" href="http://viewer.zmags.com/publication/a1afbafc?page=72"> Table 1 continued. Niraparib NOVA study, Phase II</a> <a title="EMJ Oncology 7.1 2019 page 73" href="http://viewer.zmags.com/publication/a1afbafc?page=73"> with TNBC, 14.6% have germline DNA repair gene mu</a> <a title="EMJ Oncology 7.1 2019 page 74" href="http://viewer.zmags.com/publication/a1afbafc?page=74"> as an indicator for targeted therapy with P</a> <a title="EMJ Oncology 7.1 2019 page 75" href="http://viewer.zmags.com/publication/a1afbafc?page=75"> bioinformatics, will hopefully contribute to </a> <a title="EMJ Oncology 7.1 2019 page 76" href="http://viewer.zmags.com/publication/a1afbafc?page=76"> References 1. Miki Y et al. A strong candida</a> <a title="EMJ Oncology 7.1 2019 page 77" href="http://viewer.zmags.com/publication/a1afbafc?page=77"> Branchial Cleft Cyst – A Misdiagnosed </a> <a title="EMJ Oncology 7.1 2019 page 78" href="http://viewer.zmags.com/publication/a1afbafc?page=78"> Figure 1: 5x4 cm round swelling in right side of </a> <a title="EMJ Oncology 7.1 2019 page 79" href="http://viewer.zmags.com/publication/a1afbafc?page=79"> right side of the neck. Dissection was performed </a> <a title="EMJ Oncology 7.1 2019 page 80" href="http://viewer.zmags.com/publication/a1afbafc?page=80"> of the entity coupled with good radiographic assi</a> <a title="EMJ Oncology 7.1 2019 page 81" href="http://viewer.zmags.com/publication/a1afbafc?page=81"> Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib an</a> <a title="EMJ Oncology 7.1 2019 page 82" href="http://viewer.zmags.com/publication/a1afbafc?page=82"> NERATINIB WE ARE THE SCIENTISTS WHO SAY The dru</a> <a title="EMJ Oncology 7.1 2019 page 83" href="http://viewer.zmags.com/publication/a1afbafc?page=83"> have been made to develop agents that directly in</a> <a title="EMJ Oncology 7.1 2019 page 84" href="http://viewer.zmags.com/publication/a1afbafc?page=84"> are predominantly localised in the nucleus w</a> <a title="EMJ Oncology 7.1 2019 page 85" href="http://viewer.zmags.com/publication/a1afbafc?page=85"> formation. Important additional proteins, such </a> <a title="EMJ Oncology 7.1 2019 page 86" href="http://viewer.zmags.com/publication/a1afbafc?page=86"> Plasma membrane prenylation atorvastatin K-RAS </a> <a title="EMJ Oncology 7.1 2019 page 87" href="http://viewer.zmags.com/publication/a1afbafc?page=87"> IMMUNOTHERAPY EFFICACY HDAC INHIBITORS AS ENHANC</a> <a title="EMJ Oncology 7.1 2019 page 88" href="http://viewer.zmags.com/publication/a1afbafc?page=88"> the safe maximum plasma concentration and</a> <a title="EMJ Oncology 7.1 2019 page 89" href="http://viewer.zmags.com/publication/a1afbafc?page=89"> </a> <a title="EMJ Oncology 7.1 2019 page 90" href="http://viewer.zmags.com/publication/a1afbafc?page=90"> Optimised Tumour Sampling and Processing by a M</a> <a title="EMJ Oncology 7.1 2019 page 91" href="http://viewer.zmags.com/publication/a1afbafc?page=91"> Received: 04.05.19 Accepted: </a> <a title="EMJ Oncology 7.1 2019 page 92" href="http://viewer.zmags.com/publication/a1afbafc?page=92"> Multiplexed testing enlarged to EGFR, ALK, E</a> <a title="EMJ Oncology 7.1 2019 page 93" href="http://viewer.zmags.com/publication/a1afbafc?page=93"> While larger needles allow obtaining enough tissu</a> <a title="EMJ Oncology 7.1 2019 page 94" href="http://viewer.zmags.com/publication/a1afbafc?page=94"> lung cancer and in the diagnosis of mediastinal p</a> <a title="EMJ Oncology 7.1 2019 page 95" href="http://viewer.zmags.com/publication/a1afbafc?page=95"> tumour tissue samples, and a correct handling of </a> <a title="EMJ Oncology 7.1 2019 page 96" href="http://viewer.zmags.com/publication/a1afbafc?page=96"> benefits.35 Due to the ability of NGS techniques t</a> <a title="EMJ Oncology 7.1 2019 page 97" href="http://viewer.zmags.com/publication/a1afbafc?page=97"> To circumvent tissue decalcificatio</a> <a title="EMJ Oncology 7.1 2019 page 98" href="http://viewer.zmags.com/publication/a1afbafc?page=98"> Advanced adenocarcinoma; NSCLC nos; squamous cell</a> <a title="EMJ Oncology 7.1 2019 page 99" href="http://viewer.zmags.com/publication/a1afbafc?page=99"> aiom-2018-neoplasie-del-polmone/. Last accessed 1</a> <a title="EMJ Oncology 7.1 2019 page 100" href="http://viewer.zmags.com/publication/a1afbafc?page=100"> Follow-Up of Accessory Breast Cancer Patient: </a> <a title="EMJ Oncology 7.1 2019 page 101" href="http://viewer.zmags.com/publication/a1afbafc?page=101"> incidence of supernumerary breast and ectopic bre</a> <a title="EMJ Oncology 7.1 2019 page 102" href="http://viewer.zmags.com/publication/a1afbafc?page=102"> 30 g, and to which bio-section showed a gr</a> <a title="EMJ Oncology 7.1 2019 page 103" href="http://viewer.zmags.com/publication/a1afbafc?page=103"> IHC results were not exclusively positi</a> <a title="EMJ Oncology 7.1 2019 page 104" href="http://viewer.zmags.com/publication/a1afbafc?page=104"> frequent site followed by the area inferior to th</a> <a title="EMJ Oncology 7.1 2019 page 105" href="http://viewer.zmags.com/publication/a1afbafc?page=105"> carcinoma,16 except for some difference</a> <a title="EMJ Oncology 7.1 2019 page 106" href="http://viewer.zmags.com/publication/a1afbafc?page=106"> consideration for an axillary mass in a peripuber</a> <a title="EMJ Oncology 7.1 2019 page 107" href="http://viewer.zmags.com/publication/a1afbafc?page=107"> Share your knowledge with the world. </a>